PositiveID Corporation's iglucose Mobile Health Solution for Diabetes Management to be Featured at American Telemedicine Association Annual International Meeting & Exhibition 2011

        Print
| Source: PositiveID Corporation

DELRAY BEACH, Fla., April 28, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID), a leader in next generation patient monitoring and diagnostics, announced today that its iglucose mobile health solution for diabetes management will be featured at the American Telemedicine Association Annual International Meeting and Exhibition 2011 in Tampa, Florida, May 1-3. iglucose uses the power of mobile technology to revolutionize the way individuals with diabetes manage their condition. iglucose wirelessly communicates data from data-capable glucometers to the iglucose database, at which point blood glucose readings can be shared with family members and health care professionals, empowering individuals with diabetes to be more engaged in the self-management of their condition. The product will be demonstrated live at PositiveID's booth #1340.

PositiveID's iglucose system is a wireless communication solution that facilitates diabetes management by automatically creating logs and journals, which the American Diabetes Association says are an important assessment of an individual's response to their diabetes care plan. iglucose provides healthcare professionals new insight which may be helpful to ensure patient compliance and data accuracy, as well as to aid in insurance reimbursement. This product has not been cleared for sale by the United States Food and Drug Administration.

The ATA Annual Meeting is the premier educational and networking event for individuals involved in health technology and remote medical services. ATA 2011 is a forum for reaching the world's largest gathering of telehealth professionals--over 4000 researchers, clinicians, administrators, technicians and entrepreneurs, all focused on the development of telemedicine.

According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion.

About PositiveID Corporation

PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com.  

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the ability of iglucose to use the power of mobile technology to revolutionize the way individuals with diabetes manage their condition; the ability of iglucose to wirelessly communicate data from data-capable glucometers to the iglucose database, at which point blood glucose readings can be shared with family members and health care professionals, empowering individuals with diabetes to be more engaged in the self-management of their condition; the ability of iglucose to facilitate diabetes management by automatically creating logs and journals; the likelihood that iglucose provides healthcare professionals new insight which may be helpful to ensure patient compliance and data accuracy, as well as to aid in insurance reimbursement; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully commercialize iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Allison Tomek
561-805-8000


Dan Schustack
CEOcast
212-732-4300